Mavacamten/reduces excessive sarcomere contraction, anti-HCM direction

Description

This product is Mavacamten (research codes MYK-461, SAR439152) with CAS No. 1642288-47-8. It is a synthetic small-molecule compound and an active pharmaceutical ingredient of a newly approved global innovative cardiovascular drug. Its molecular formula is C₁₅H₁₉N₃O₂ with a molecular weight of approximately 273.33. It normally appears as white to off-white solid or powder, and its purity can reach over 98% as determined by HPLC. As a commercial pharmaceutical raw material and research compound, this product can be supplied in different specifications including API grade and reagent grade according to applications, mainly for pharmaceutical companies, formulation manufacturers and research institutions. It is one of the highly concerned candidates in the field of cardiovascular drug research and development in recent years. The product shall be stored in a sealed, light-proof place with cool and dry conditions.

Key Effects

The contraction of the heart relies on a key protein called "myosin", which acts as the "engine" of the heart muscle. In patients with certain heart diseases such as hypertrophic cardiomyopathy, this "engine" becomes overactive, causing excessive myocardial contraction and abnormal thickening of the ventricular wall, which impairs normal cardiac function. Mavacamten works by moderately inhibiting the activity of cardiac myosin, restoring balance to heart contraction, thereby reducing obstruction of the ventricular outflow tract and improving cardiac structure and function. It is the world's first approved drug of this mechanism, offering a brand-new approach for the treatment of obstructive hypertrophic cardiomyopathy, and is of landmark significance in clinical practice and pharmaceutical research and development.

Its specific functions can be summarized as follows:
Regulate myocardial contraction: Moderately inhibit cardiac myosin activity to restore normal balance of heart contraction strength;
Relieve ventricular obstruction: Help reduce the degree of ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy;
Improve cardiac function: Assist in ameliorating cardiac structure and functional status and alleviating patients' symptoms;
Value in new drug research and development: As the world's first approved raw material for drugs of this mechanism, it serves as an important subject for cardiovascular new drug research;
Reference standard and control function: Can be used for quality research, content determination and impurity control of related preparations.

Applications

This product is an innovative drug active pharmaceutical ingredient (API), mainly targeting the production and research & development of cardiovascular pharmaceutical preparations, with clear application directions and high professionalism.
Its main application fields can be summarized as follows:
Treatment of hypertrophic cardiomyopathy: Used as the API for drugs treating obstructive hypertrophic cardiomyopathy;
Research and development of new cardiovascular drugs: Served as a lead compound or research subject for pharmaceutical research on myocardial contraction regulation mechanisms;
Preparation production: Used for raw material supply of relevant oral preparations such as tablets;
Quality research and testing: Applied as reference standards for content determination and impurity research of APIs and preparations;
Export trade and raw material supply: Supplied as pharmaceutical raw materials to pharmaceutical factories, preparation manufacturers, research institutions and traders, with specifications available according to customer requirements.